Kanut Laoharawee

Kanut Laoharawee is a graduate student in the Molecular Cellular Developmental Biology and Genetics Program at the University of Minnesota, Minneapolis, MN, USA. He is currently working under Dr. Branden Moriarity in the Department of Pediatrics Medical School at the University of Minnesota. Kanut received his Bachelor of Science in Clinical Laboratory from Chulalongkorn University, Bangkok, Thailand, and his Masters in Biological Sciences from the University of Minnesota, MN, USA.

Kanut’s Masters’ focus was on using Adeno Associated Viral (AAV) vector for in vivo gene therapy to treat a mouse model of mucopolysachharidosis type II (MPS II), an inherited lysosomal storage disorder. As a Ph.D. student in Dr. Moriarity’s Lab, Kanut continues his pursuit of a novel and effective therapy to treat lysosomal storage disorders, now by using CRISPR/Cas9 system to edit primary B cells ex vivo. His goal is to express a therapeutic -L-iduronidase (IDUA) enzyme and enable an adoptive transfer of the engineered B cells into a mouse model of Hurler syndrome as a novel, cell-based, enzyme-replacement therapy.

Publications:

CRISPR/Cas9-Mediated Genome Engineering of Primary Human B Cells.

Method Mol Biol. 2020 | PMID:32006415

Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic Osteosarcoma

Mol Cancer Ther. Dec 2020 | PMID: 32999043

PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma

Bone. Jul 2020 | PMID: 32251854

ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome

Mol Ther. Jan 2019 | PMID: 30528089

Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease

Sci Rep. Aug 2018 | PMID: 30108345

Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing

Mol Ther. Apr 2018 | PMID: 29580682

Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer

Human Gene Ther. Aug 2017 | PMID: 28478695